Скачать или смотреть Implications of EV 302: How Do We Sequence Drug Therapies in Bladder Cancer by Dr. Gupta

Shilpa Gupta, MD, explores the evolving treatment paradigm in metastatic urothelial carcinoma following the EV-302 trial.

In this 6-minute presentation, Dr. Gupta reviews past treatment paradigms, explaining that, before the EV-302 trial, cisplatin-eligible patients typically received cisplatin-based chemotherapy followed by immunotherapy upon progression.

The current treatment paradigm prioritizes EV plus pembrolizumab as the frontline standard, followed by platinum-based chemotherapy upon progression. Dr. Gupta stresses that future research must optimize treatment sequences and develop novel therapies for patients who progress on EV plus pembrolizumab. Comprehensive genomic and IHC testing is essential for guiding treatment decisions and ensuring patients receive targeted therapies.